To assess the efficacy of viscosupplementation (HA) in hip osteoarthritis (OA) pain, disability and adverse events.Pubmed, EMBASE, Cochrane Library, ClinicalTrials.gov database and specific journals up to March 2017.Randomized controlled trials comparing HA with any other intra-articular injection.Performed according to Cochrane/GRADE criteria. Two authors extracted data, assessed risk of bias and quality of evidence. Random-effects meta-analysis was conducted. Protocol registered on PROSPERO under CRD42015017312 DATA SYNTHESIS: Eight RCTs were retrieved (n=807): four comparing HA to placebo (PBO); three with platelet-rich plasma (PRP), three with methylprednisolone (MPA), and one mepivacaine (MPV). Some RCTs had three arms. There is VERY LOW evidence that HA is not superior to PBO in pain at 3 months (SMD=-0.06 [95

作者：Victor Figueiredo, Leite；Jo?o Eduardo, Daud Amadera；Anna Maria, Buehler

来源：Archives of physical medicine and rehabilitation 2017 年